(2,3-Dihydroxy-propyl)-(2,3-di-O-myristoyl-glyceryl)-ether | 103397-32-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: (2,3-Dihydroxy-propyl)-(2,3-di-O-myristoyl-glyceryl)-ether
• 英文别名: [3-(2,3-Dihydroxypropoxy)-2-tetradecanoyloxypropyl] tetradecanoate
• CAS: 103397-32-6
• 化学式: C₃₄H₆₆O₇
• 分子量: 586.894
• InChiKey: COLKUDIILOHEMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.1
• 重原子数：
  41
• 可旋转键数：
  34
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] PROSTACYLIN COMPOSITIONS AND METHODS FOR USING THE SAME<br/>[FR] COMPOSITIONS DE PROSTACYCLINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：INSMED INC

  公开号：WO2015138423A1

  公开（公告）日：2015-09-17

  The present invention relates to pharmaceutical compositions comprising a prostacyclin, a cationic compound, and a surfactant. Particulate compositions, including liposomal, solid nanoparticulate prostacyclin compositions, including treprostinil and deuterated treprostinil formulations comprising cationic compound and the surfactant are also described. The present invention also relates to a system comprising the pharmaceutical composition and an inhalation device. Methods for treating pulmonary hypertension and portopulmonary hypertension with the compositions and systems described herein are also provided.